English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/112778
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorArtigas, Francesc-
dc.contributor.authorRiga, Maurizio-
dc.contributor.authorCelada, Pau-
dc.contributor.authorSánchez, Connie-
dc.date.accessioned2015-03-20T13:02:24Z-
dc.date.available2015-03-20T13:02:24Z-
dc.date.issued2013-12-09-
dc.identifier.citationACNP 52nd Annual Conference (2013)-
dc.identifier.urihttp://hdl.handle.net/10261/112778-
dc.descriptionPóster presentado en: ACNP (American College of Neuropsychopharmacology) 52nd Annual Conference, celebrada del 8 al 12 de diciembre de 2013 en Hollywood, Florida (Estados Unidos)-
dc.descriptionAbstract publicado en: Neuropsychopharmacology 38:S252 (2013). ISSN: 0893-133X. eISSN: 1740-634X. DOI:10.1038/npp.2013.279-
dc.rightsclosedAccess-
dc.subject5-HT3 receptor-
dc.subjectAntidepressant-
dc.subjectSerotonin-
dc.subjectVortioxetine-
dc.subjectGABAergic interneurons-
dc.subjectPyramidal Neurons,-
dc.subjectPrefrontal Cortex-
dc.subjectDorsal Raphe Nucleus-
dc.title5-HT3 receptors are involved in the mechanism of action of the new antidepressant drug vortioxetine-
dc.typepóster de congreso-
dc.identifier.doi10.1038/npp.2013.279-
dc.relation.publisherversionhttp://dx.doi.org/10.1038/npp.2013.279-
dc.date.updated2015-03-20T13:02:25Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
Appears in Collections:(IIBB) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.